Pharmabiz

Personalis publishes a new study in Clinical Cancer Research to monitor cancer immunotherapy response across solid tumours

Personalis publishes a new study in Clinical Cancer Research to monitor cancer immunotherapy response across solid tumours: Fremont, California Friday, December 19, 2025, 16:00 Hr ...
Pharmabiz

Gleneagles Hospital Mumbai introduces the Institute of Onco-Science: A unified centre of excellence for cancer care

As India faces an alarming surge in cancer incidence, Gleneagles Hospital, Parel, Mumbai, has unveiled the Institute of Onco-Science, a comprehensive and fully coordinated cancer care centre designed ...
Pharmabiz

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study: Friendswood, Texas Friday, December 19, 2025, 15:00 H ...
Pharmabiz

Symeres earns first SBTi approval as part of long-term sustainability journey

Symeres earns first SBTi approval as part of long-term sustainability journey: Nijmegen, Netherlands Friday, December 19, 2025, 18:00 Hrs [IST] Symeres, a leading contract researc ...
Pharmabiz

IPC 2025 begins on high note amid RGHUS, Karnataka FDA push for reliability of medicines

IPC 2025 begins on high note amid RGHUS, Karnataka FDA push for reliability of medicines: Nandita Vijayasimha, Bengaluru Friday, December 19, 2025, 14:30 Hrs [IST] Indian Pharmace ...
Pharmabiz

Astellas Pharma announces positive topline results from phase 3 EV-304 clinical trial of Padcev plus Keytruda

Astellas Pharma announces positive topline results from phase 3 EV-304 clinical trial of Padcev plus Keytruda: Tokyo Friday, December 19, 2025, 10:00 Hrs [IST] Astellas Pharma Inc ...
Pharmabiz

EMA validates Type II Variation marketing authorization application of Datroway as first-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy

EMA validates Type II Variation marketing authorization application of Datroway as first-line treatment for patients with metastatic TNBC who are not candidates for immunotherapy ...
Pharmabiz

UK MHRA updates guidance on the Health Institution Exemption to support safe use of medical devices

UK MHRA updates guidance on the Health Institution Exemption to support safe use of medical devices: United Kingdom Friday, December 19, 2025, 12:00 Hrs [IST] Patients across Engl ...
Pharmabiz

Takeda’s zasocitinib landmark phase 3 plaque psoriasis data show promise to deliver clear skin in a once-daily pill, catalyzing a new era of treatment

Takeda’s zasocitinib landmark phase 3 plaque psoriasis data show promise to deliver clear skin in a once-daily pill, catalyzing a new era of treatment: Osaka, Japan Friday, Dece ...
Pharmabiz

Norgine inks exclusive licensing agreement with Vir Biotechnology to enhance hepatology and specialty portfolio

Norgine inks exclusive licensing agreement with Vir Biotechnology to enhance hepatology and specialty portfolio: Uxbridge, England Friday, December 19, 2025, 14:00 Hrs [IST] Norgi ...
Pharmabiz

Lifecore Biomedical inks CDMO services agreement with global multinational pharmaceutical customer

Lifecore Biomedical inks CDMO services agreement with global multinational pharmaceutical customer: Chaska, Minnesota Friday, December 19, 2025, 11:00 Hrs [IST] Lifecore Biomedica ...
Pharmabiz

TempraMed Technologies expands US manufacturing capacity with new production facility in Florida

TempraMed Technologies Ltd, a medical technology innovator transforming how temperature-sensitive medications are stored and managed, announced that it has opened an additional United States ...